MedPath

Comparison of non-bismuth concomitant and standard triple therapies as a first-line treatment option for Helicobacter pylori in Japa

Not Applicable
Conditions
Helicobacter pylori infection
Registration Number
JPRN-UMIN000018164
Lead Sponsor
Tokai University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
220
Inclusion Criteria

Not provided

Exclusion Criteria

Patients were excluded from the study if they were younger than 20 years or older than 80 years, were allergic to the drugs used in this therapy. Patients who are disqualified for the study by physicians.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Comparison of the eradication rate of the two regimens, PPI+AMPC +CAM+MNZ versus PPI+AMPC+CAM for first line
Secondary Outcome Measures
NameTimeMethod
Comparison of the safety of the two regimens, PPI+AMPC +CAM+MNZ versus PPI+AMPC+CAM for first line
© Copyright 2025. All Rights Reserved by MedPath